News

Upcoming Investor Conferences Highlight Ascentage Pharma's Innovations

Upcoming Investor Conferences Highlight Ascentage Pharma's Innovations

Ascentage Pharma’s Engagement in Upcoming Investor Conferences

Ascentage Pharma Group International (NASDAQ: AAPG; HKEX: 6855) continues to stand at the forefront of biopharmaceutical innovation. This September, the company is gearing up for an integral presence in the investor community by participating in three pivotal investor conferences. These events showcase Ascentage Pharma's commitment to advancing novel therapies to meet critical medical needs in the realm of cancer treatment.

Key Conferences and Presentations

Ascentage Pharma's management team will take part in a series of discussions designed to elaborate on the company's mission and developments:

Citi's 2025 Biopharma Back to School

This conference is scheduled for September 3, where a fireside chat at 4:00 pm EDT will unfold. Attendees will gain insights into the innovative strategies Oncentage Pharma is employing in the healthcare landscape.

Cantor Global Healthcare Conference 2025

On September 4, a fireside chat will be held at 2:45 pm EDT. This will serve as another platform for Ascentage Pharma to highlight its focus on addressing significant therapeutic gaps in cancer care.

H.C. Wainwright 27th Annual Global Investment Conference

The company will conclude its conference participation with a presentation on September 10 at 1:30 pm EDT. This event is crucial for engaging potential investors and cultivating partnerships for future innovation.

About Ascentage Pharma Group International

Ascentage Pharma is recognized as a global, integrated biopharmaceutical company dedicated to discovering and developing cutting-edge therapies aimed at unmet medical needs in oncology. The firm has developed a promising portfolio rich in innovative drug products, focusing on inhibitors that target critical proteins essential to the apoptotic pathway, including Bcl-2 and MDM2-p53, along with next-generation kinase inhibitors.

Innovative Treatment Solutions and Pipeline Development

The company’s flagship product, Olverembatinib, marks a significant milestone as the first third-generation BCR-ABL1 inhibitor. Approved for treating patients with chronic myeloid leukemia (CML), it stands out for its efficacy against T315I mutations. This drug is included in the China National Reimbursement Drug List (NRDL), enhancing accessibility for patients. In addition, Ascentage Pharma is undertaking an FDA-cleared registrational Phase III trial for Olverembatinib, aimed at further solidifying its effectiveness across various patient demographics.

Additionally, Lisaftoclax, Ascentage Pharma's second approved drug, serves as a novel Bcl-2 inhibitor intended for various hematologic malignancies. Its approval by China’s National Medical Products Administration (NMPA) to treat chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) patients provides a crucial new option, particularly for those who have undergone previous treatment regimens.

Global Collaborations and Future Directions

Ascentage Pharma's reach extends through strategic partnerships with industry leaders like Takeda, AstraZeneca, Merck, and Pfizer, as well as collaborations with premier research institutions. This vast network aids in enhancing their research and development initiatives, further pushing the boundaries of cancer therapy.

Contact Information for Inquiries

For those seeking further information on Ascentage Pharma's conference participations or product details, the following contact points are provided:

Investor Relations:
Hogan Wan, Head of IR and Strategy
Ascentage Pharma
Hogan.Wan@ascentage.com
+86 512 85557777

Stephanie Carrington
ICR Healthcare
AscentageIR@icrhealthcare.com
+1 (646) 277-1282

Media Relations:
Jon Yu
ICR Healthcare
AscentagePR@icrhealthcare.com
+1 (646) 677-1855

Frequently Asked Questions

What is Ascentage Pharma's core focus?

Ascentage Pharma is dedicated to developing innovative therapies for cancer treatment, addressing critical unmet medical needs.

When are the upcoming investor conferences?

Ascentage Pharma will participate in key conferences on September 3, 4, and 10 of this year.

What products has Ascentage Pharma developed?

The company has developed significant therapies like Olverembatinib and Lisaftoclax, targeting various cancers.

How can investors learn more about Ascentage Pharma?

Investors can access information at Ascentage Pharma’s investor relations section on their website.

Who should be contacted for investor inquiries?

For investor relations, Hogan Wan and Stephanie Carrington are key contacts at Ascentage Pharma and ICR Healthcare, respectively.

About The Author

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.

Top 10 Most Recent News Articles

Market Timing Risks in Retirement: Kelly's Take

Updated Category News Views 112

Why Market Timing Could Cripple Your Nest Egg The stock market's got its fair share of curveballs, but one that can really mess with your retirement plan is this sneaky thing called sequence of returns risk. Get this—it's the timing of those pesky market dips that can seriously mess up how long your savings last. The Danger Lurking in Return Order Seasoned traders like...

Continue Reading
PG&E Halts Service; Groups Demand Regulatory Action

Updated Category News Views 193

Pending Storm Over PG&E's Service Delays It's rare that you hear a utility company flat-out say it can't afford to keep the lights on. Yet here we are, staring down the barrel of some unsettling news for 25,000 PG&E customers. They've been warned they might cool their heels for an extra six months before their service is up and running. As if that's not dicey enough, $2...

Continue Reading
Endava Class Action: Investor Concerns Unveiled

Updated Category News Views 88

What's Happened with Endava? Endava plc, trading under NYSE:DAVA, just got pummeled. A lawsuit is making waves, targeting investors who bought into Endava between September 2025 and 2026. What's the fuss about? Their stock tanked 25% on September 22, 2026, following an unsettling revelation: the company disclosed serious management and potential accounting problems. A...

Continue Reading
Skechers Facing Class Action: Investors Urged to Act

Updated Category News Views 93

Skechers Under Fire: Fraud Allegations Surface Alright, if you've been around the stock block a while, you know these stories can often read like a suspense novel. Plot twist: Skechers U.S.A., Inc. (formerly NYSE: SKX) is now facing some serious accusations. There's a class action lawsuit claiming that some shady dealings went down during the company's $9.4 billion...

Continue Reading
Centerspace Sale Faces Scrutiny Amid Investor Concerns

Updated Category News Views 40

Potential Undervaluation Looms Large over Centerspace Sale On a crisp October day, the saga of Centerspace's proposed sale to Independence Realty Trust (NYSE: IRT) is stirring the pot. Charles C. Foti, Jr., Esq., and the law firm Kahn Swick & Foti, LLC are throwing a wrench into the works, questioning the soundness of the whole shebang. The deal, valued at 3.800 shares of...

Continue Reading
Medline's Decade-Long WRAP Partnership: More Than Labels

Updated Category News Views 183

A Decade of Trust and Responsibility Here we go, folks—Medline is toasting 10 years with WRAP, and this ain't just fluffy PR spin. When two big players like these lock arms over responsible manufacturing, it's a signal worth paying attention to, and not just for the ethics alone. Production practices that prioritize transparency and worker rights have ramifications...

Continue Reading
Globe Life Faces 8% Stock Dip Amidst Legal Scrutiny

Updated Category News Views 41

Trouble Brews for Globe Life Investors Brace yourselves, folks. Globe Life Inc. (NYSE: GL) has found itself slap-bang in the middle of a potentially messy legal quagmire. The $7 million in excess Medicare Supplement claims that popped up due to a snail-like processing delay by the Centers for Medicare & Medicaid Services (CMS) have sent investors scrambling. And oh boy,...

Continue Reading
Veterans, Lawmakers Forge Paths in Spokane Forum

Updated Category News Views 101

Spokane Forum Sparks Action for Veterans' Policies Gonzaga University turned into a powerhouse of dialogue and determination as the Wounded Warrior Project (WWP) gathered over 145 veterans, elected officials, and advocate groups to hash out critical policy priorities. We're talking high-stakes discussions with real consequences, not just some feel-good meet-up. A...

Continue Reading
United Vein Expands Vero Beach Network for Specialized Care

Updated Category News Views 191

Simplifying Vein Healthcare in Vero Beach Out of all the surprises life throws, leg cramps and bulging veins seem like small potatoes—until they're not. That's why folks in Vero Beach got a new lifeline today with the United Vein & Vascular Centers opening another clinic. At the crossroads of the 37th Street medical district, this place puts specialized vein care right...

Continue Reading
Meta's Bold Move: $25B Offering and New Stocks

Updated Category News Views 13

Meta's New Financial Adventure Well, when Meta talks money, you better believe the market listens. This time, they’ve got a whopping pair of offerings on the table—one for depositary shares and another for their Class A common stock. Meta, under the ticker NASDAQ:META, isn't holding back, with a $25 billion upsized offering that's bound to rattle some cages. A Deeper...

Continue Reading

Top 5 Most Recently Viewed Articles

CoStar Group Unveils Ambitious Buyback and Growth Strategies

Updated Category News Views 126

CoStar Group, Inc. Financial Initiatives CoStar Group, Inc. (NASDAQ: CSGP) has recently announced an exciting and strategic expansion plan aimed at maximizing growth and increasing shareholder value. As part of its ambitious approach, CoStar has introduced a robust $1.5 billion share repurchase program after successfully completing a previous $500 million buyback in 2025....

Continue Reading
AI and IoT Drive Growth in Fire Protection Systems

Updated Category News Views 90

AI and IoT Drive Growth in Fire Protection Systems The global market for fire protection systems is poised for substantial growth, with projections indicating an impressive increase of USD 14.58 billion during the period from 2024 to 2028. This growth corresponds to a compound annual growth rate (CAGR) of 6.78%, highlighting the beneficial impact of cutting-edge...

Continue Reading
Hyundai Motor's Heritage Initiative Celebrates Iconic Models

Updated Category News Views 313

Celebrating Iconic Vehicles: Hyundai Motor's Heritage Campaign Hyundai Motor Company has officially unveiled a heritage campaign dedicated to honoring its iconic mid-size sedans, the STELLAR and SONATA, marking a significant milestone for the SONATA's 40th anniversary. This campaign reflects the rich history and technological achievements of Hyundai, showcasing its...

Continue Reading
Experience Ultimate Relaxation with Acqualina's New Spa Treatment

Updated Category News Views 208

Rejuvenate with Acqualina Spa's Reviving Massage Treatment Acqualina Spa, renowned for its exceptional services within the luxurious Acqualina Resort, has unveiled a new addition to its treatment menu: the Reviving Massage for Hands & Feet. This 50-minute therapy is designed to refresh those often-neglected areas, providing an essential retreat for hands and feet that...

Continue Reading
HMH Distributes Historic Artwork to Northeast Museums

Updated Category News Views 19

A Treasure Chest of Art Finds New Homes When it comes to donating art, HMH isn't just about flipping a few pages of history; they're turning whole chapters. HMH, with a legacy stretching back centuries in the heartland of Boston, decided to part ways with 20 pieces of iconic art, spreading cultural seeds across some prominent northeastern museums. These aren't just any...

Continue Reading